CCL3 Recombinant Rabbit Monoclonal Antibody (1H20L19), Invitrogen™

Description

Intact IgG appears on a non-reducing gel as ∽150 kDa band and upon reduction generating a ∽25 kDa light chain band and a ∽50 kDa heavy chain. Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.

Both MIP-1alpha and MIP-1beta are structurally and functionally related CC chemokines. They participate in host response to invading bacterial, viral, parasite and fungal pathogens by regulating the trafficking and activation state of selected subgroups of inflammatory cells (e.g. macrophages, lymphocytes and NK cells). While both MIP-1alpha and MIP-1beta exert similar effects on monocytes, their effect on lymphocytes differ; with MIP-1alpha selectively attracting CD8+ lymphocytes, and MIP-1beta selectively attracting CD4+ lymphocytes. Additionally, MIP-1alpha and MIP-1beta have also been shown to be potent chemoattractants for B cells, eosinophils and dendritic cells. Both human and murine MIP-1alpha and MIP-1beta are active on human and murine hematopoietic cells.